Amneal Pharmaceuticals Stock News

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The U.S. Food and Drug Administration ((FDA)) approved four generic injectables products from Amneal Pharmaceuticals (AMRX).Dexamethasone sodium phosphate injection, USP 10…

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $83.5 million in cash.  The acqui

Amneal Pharmaceuticals, Inc. (NYSE:AMRX)s share price gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $4.27, but opened at $4.51. Amneal Pharmaceuticals shares last traded at $4.42, with a volume of 11,312 shares traded. Specifically, CEO Chirag K. Patel acquired 100,000 shares of the companys stock in []

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) CEO Chirag K. Patel bought 100,000 shares of the companys stock in a transaction that occurred on Wednesday, December 15th. The shares were bought at an average price of $4.13 per share, for a total transaction of $413,000.00. The transaction was disclosed in a legal filing with the SEC, which can []

Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati

The Hydroxychloroquine Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Hydroxychloroquine Market study includes research on the

The global Shoulder Pain Treatment market size is projected to reach US$ 3.6 Billion by 2027, at a CAGR of 8.1% during 2021-2027. Globally, the geriatric population is growing at an unprecedented rate. Shoulder pain is a frequent and debilitating

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively Amneal). As part of the settlement, TherapeuticsMD granted to Amneal a license to commercialize Amneals generic version of BIJUVA (1 mg estradiol and 100 mg p

TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX). Bijuva is a prescription medicine used to tr

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has received an average recommendation of Buy from the seven research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target []

Shares of Amneal Pharmaceuticals, Inc. have earned a consensus rating of Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One